Type 2 diabetes treatment pathway comparison
This comparison table summarises recommendations on the management of hyperglycaemia in adults with type 2 diabetes from ADA/EASD, NICE, and SIGN.
Type 2 diabetes: frailty in older people
Summary covers glycaemic targets for older people, priorities for improving high-quality diabetes care, and a useful frailty assessment pathway.
Pancreatic exocrine insufficiency guideline
This management algorithm was developed by a multidisciplinary expert panel: Hambling C et al with the support of a grant from Mylan Ltd.
SIGN type 2 diabetes guideline
This summary provides key recommendations on lifestyle management, treatment options, diabetic CVD, and CKD. Includes a useful treatment algorithm
Educational resources
Ozempic® ▼ (semaglutide) 1.34 mg/ml once‑weekly GLP-1 RA
Commissioned by Novo Nordisk Limited
Semaglutide 0.25 mg, 0.5 mg and 1 mg solution for injection in pre-filled pen (Ozempic®▼) SMC No. (2092)
Funded by Novo Nordisk Limited
Related Guidelines in Practice articles
-
Type 2 diabetes: the role of the practice pharmacist
Muhammad Siddiqur Rahman highlights the integral role of practice-based pharmacists in managing type 2 diabetes
-
Co-morbidities in type 2 diabetes
Dr Kevin Fernando describes eight common co-morbidities in patients with type 2 diabetes and how the co-existing conditions should be managed
-
Type 2 diabetes: what are the benefits and risks of glucose-lowering agents?
Dr Kevin Fernando explains how SIGN 154 offers evidence-based guidance on glucose control therapies for people with type 2 diabetes
-
Top tips: type 2 diabetes
Dr Kevin Fernando provides top tips on diagnosing and managing type 2 diabetes and identifying people at high risk
-
An innovative diabetes service redesign in Wakefield
Dr Dinesh Nagi provides insight into an integrated model of care provided by primary care and specialist diabetes teams